The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies

Levetiracetam Will Maintain Its Status as the Epilepsy Market Leader and Will Garner Sales of Approximately $540 Million in 2019, According to Findings from Decision Resources

Oct 21, 2010, 08:00 ET from Decision Resources

BURLINGTON, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, the epilepsy drug market will remain relatively flat, increasing from $2.8 billion in 2009 to $2.9 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Epilepsy forecast a decline in overall sales through 2014 due to generic erosion, specifically within the second-generation antiepileptic drug (AED) class, which will lose approximately $400 million by 2014. Generic erosion within the epilepsy market remains relatively conservative but several popular second-generation AEDs will contend with strong generic competition over the next several years. Nevertheless, the market will recover as a result of uptake of both currently-marketed and emerging higher-priced third-generation AEDs.

"Through 2019, the majority of AEDs will be generically available, creating negative pressure on market growth," said Decision Resources Analyst Nadja Rozovsky, Ph.D. "However, emerging agents, combined with greater uptake of the already-available and mostly branded third-generation AEDs, will temper the impact of generic AEDs, and the market will recover by 2019."

The findings reveal that levetiracetam (UCB's Keppra/Keppra XR, generics) is the current market leader in epilepsy. Driven by its preferred use as both a first-line adjunctive therapy and increasingly as first-line monotherapy, levetiracetam will continue to lead the market in 2019 with approximately $540 million in major-market sales.

The continued uptake of current third-generation AEDs—particularly UCB's Vimpat and Sunovion/Bial/Eisai's Zebinix—and uptake of the emerging AEDs UCB's Rikelta, Valeant/GlaxoSmithKline's Potiga and Eisai's perampanel will offer alternative therapeutic options as adjunctive agents, according to the findings. Because these drugs will be used in later lines of adjunctive treatment and compete with established AEDs, however, they will experience only moderate uptake and earn modest sales.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources, Inc.

Christopher Comfort


SOURCE Decision Resources